How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia
Authors:
Open Access
- 3 October 2019
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (11) , 2135-2143
Abstract
Advances in our understanding of mechanisms of leukemogenesis and driver mutations in acute lymphoblastic leukemia lead to a more precise and informative sub-classification, mainly of B-acute lymphoblastic leukemia. In parallel, in recent years, novel agents have been approved for B-acute lymphoblastic leukemia therapy, and many others are in active clinical research. Among the newly recognized disease subtypes, Philadelphia-chromosome-like acute lymphoblastic leukemia is most heterogeneous and thus, diagnostically challenging. Given that this B-acute lymphoblastic leukemia subtype is associated with a poorer prognosis, improvement of available therapeutic approaches and protocols is a burning issue. We have herein summarized in a clinically relevant manner, up-to-date information regarding diagnostic strategies developed for the identification of patients with Philadelphia-chromosome-like acute lymphoblastic leukemia. Common therapeutic dilemmas, presented as several case scenarios, are also discussed. It is currently acceptable that B-acute lymphoblastic leukemia patients, treated with an aim of cure, irrespective of their age, be evaluated for a Philadelphia-chromosome-like signature as early as possible. Following Philadelphia-chromosome-like recognition, a higher risk for resistance or relapse must be realized and treatment should be modified based on patient9s specific genetic driver and clinical features. However, while active targeted therapeutic options are limited, there is much more to do than just prescribe a matched inhibitor to the identified mutated driver genes. In this review, we present a comprehensive evidence-based approach to the diagnosis and management of Philadelphia-chromosome-like acute lymphoblastic leukemia at different time points during the disease course.Keywords
This publication has 110 references indexed in Scilit:
- Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusionHaematologica, 2013
- Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2–harboring clones as main relapse-driving force in childhood ALLBlood, 2012
- Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcomeBlood, 2010
- Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemiaBlood Cells, Molecules, and Diseases, 2010
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaBlood, 2010
- Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009
- Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology GroupBlood, 2008